<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000520411"><TermName>oprelvekin</TermName><TermPronunciation>(oh-PREL-veh-KIN)</TermPronunciation><TermDefinition><DefinitionText>A drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Oprelvekin is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory.  It is a type of biological response modifier.  Also called Neumega, recombinant human interleukin-11,  and rhIL-11.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718105" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;oprelvekin&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718104" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;oprelvecina&quot;" language="es" id="_4"/><SpanishTermName>oprelvecina</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para aumentar el número de células sanguíneas, especialmente plaquetas, en algunos pacientes de cáncer que reciben quimioterapia. La oprelvecina es una forma de la interleucina-11 (una citocina normalmente elaborada por las células de sostén de la médula ósea) que se produce en el laboratorio. Es un tipo de modificador de la respuesta biológica.  También se llama interleucina-11 humana recombinada, Neumega,  y rhIL-11.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-11-13</DateFirstPublished><DateLastModified>2009-03-25</DateLastModified></GlossaryTerm>
